Document is current

Article History

Received: 18 October 2024

Accepted: 30 April 2025

First Online: 13 May 2025

Competing interests

: R.B-S. reported receiving speaker bureau fees from AstraZeneca, Daichi-Sankyo, Eli Lilly, Pfizer, Novartis, Merck, and Roche. He has also served as a consultant/advisor for AstraZeneca, Eli Lilly, Libbs, Roche, Merck, and has received support for attending medical conferences from AstraZeneca, Roche, Eli Lilly, Daichi-Sankyo, and Merck. Has received institutional research funding from AstraZeneca and Daichi-Sankyo and owns stocks in the educational company RD Educacao Medica LTDA. J.G. owns stocks in the biotechnology exchange-traded funds CNCR, IDNA, IBB, and XBI, owns stocks in Novo Nordisk, and owned stocks in Adaptive Biotechnologies, 2seventy bio, and bluebird bio. M.M. is an employee of Foundation Medicine and owns stock in Roche Holding AG. S.M.R. has received institutional research funding from Eli Lilly, Celldex Therapeutics, Bristol Myers Squibb, Tvardi Therapeutics, and Silverback Therapeutics. She has served as a scientific advisor for Pfizer, Eli Lilly, and Silverback Therapeutics. V.A. reports current employment at Olema Pharmaceuticals and stock ownership in OLMA. N.U.L. reports institutional research support from Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle Genetics (now Pfizer), Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., and Eisai; royalties from UpToDate; and travel support from Olema Pharmaceuticals and AstraZeneca. R.J. received institutional research support from Pfizer and Lilly. Consulting honoraria from Lilly, Pfizer, Novartis, and Carrick Therapeutics. E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. E.A.M. also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. S.M.T. receives institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep, Daiichi-Sankyo, Menarini/Stemline, and Jazz Pharmaceuticals; has served as an advisor/consultant for Novartis, Pfizer (SeaGen), Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi-Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Johnson&Johnson/Ambrx, Launch Therapeutics, Zuellig Pharma, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, and Summitt Therapeutics; and receives travel support from Eli Lilly, Sanofi, Gilead, Jazz Pharmaceuticals, Pfizer, and Arvinas. C.A.C.S. reported receiving speaker bureau fees from Bristol Myers Squibb. The remaining authors declare no financial or non-financial competing interests.